格隆汇11月19日丨西点药业(301130.SZ)在投资者互动平台表示，公司现有已上市产品方面，公司拥有 成熟的抗流感药物复方氨酚烷胺胶囊，以及于2025年获得批准上市的抗病毒片临床上用于治疗上呼吸道 感染及流行性感冒。公司的在研项目"瑞香素对人类疾病小鼠模型干预效果的研究"子项目"瑞香素对小 鼠病毒性肺炎模型干预效果研究"中已获得了瑞香素在病毒性肺炎治疗中具有安全性和有效性的实验结 果，已获得《瑞香素在制备治疗病毒性肺炎的药物中的应用》发明专利。 ...

Core Viewpoint - The company has recently obtained an invention patent certificate for the synthesis method of a core product, which signifies a strategic enhancement of its technological capabilities and intellectual property protection [1][2]. Group 1: Patent Acquisition - The company has received an invention patent certificate from the National Intellectual Property Administration of China for a synthesis method of Rhizoma Anemones [1]. - The synthesis method involves using gallic acid and malic acid as raw materials, with concentrated sulfuric acid as a condensation catalyst, achieving a product yield of over 90% and purity of up to 99% [1]. Group 2: Strategic Implications - The acquisition of this patent reflects not only a technological advancement but also a strategic move to strengthen core technologies and lay a foundation for future development [2]. - The company now holds two patents related to the synthesis process of Rhizoma Anemones, which will enhance its core competitiveness in technological innovation and support the development of this key product [2].

Core Points - The company has recently obtained an invention patent certificate from the National Intellectual Property Administration of the People's Republic of China [1] - The patent is titled "A Synthesis Method of Ruscogenin" and has a patent number of 8338136 [1] - The patent application date was July 28, 2025, and the authorization announcement date was October 10, 2025 [1] - The patent is owned by Jilin Xidian Pharmaceutical Technology Development Co., Ltd., and has a validity period of 20 years [1]